The use of an in vitro haemoperfusion circuit to evaluate the blood compatibility of albumin-coated Amberlite XAD-7 resin.
We have developed an in vitro haemoperfusion circuit, which closely simulates the conditions encountered in a clinical haemoperfusion, for testing the blood compatibility of new adsorbent materials. Fresh heparinised human blood is perfused for 2 hours over two model columns arranged in parallel closed circuits. The present study was performed to investigate the blood compatibility of human serum albumin-coated Amberlite XAD-7 resin. Mean platelet losses over 2 hours were greater following perfusion of the uncoated resin (44 +/- SE 5.6%) than the albumin-coated resin (17 +/- SE 2.2%) (p less than 0.01). Mean white cell losses were similar (55%) for both resins. No rises in Swank screen filtration pressure, which detects the presence of cellular aggregates in blood, were observed. Coating of XAD-7 resin with HSA therefore improves its blood compatibility with respect to platelet losses and we thus intend to use this preparation in a clinical trial of resin haemoperfusion in fulminant hepatic failure.
D000180:Acrylic Resins / Q000009:adverse effects*; D001672:Biocompatible Materials; D001773:Blood Cells / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects; D005069:Evaluation Studies as Topic; D006464:Hemoperfusion; D006801:Humans; D066298:In Vitro Techniques; D007962:Leukocytes / Q000187:drug effects; D011137:Polystyrenes; D012709:Serum Albumin
D000180:Acrylic Resins; D001672:Biocompatible Materials; D011137:Polystyrenes; D012709:Serum Albumin; C015661:amberlite XAD 7